Imagine being able to reverse the biological clock and restore youth. That's the ambitious goal of Shift Bioscience, a biotech company pioneering novel gene-based cell rejuvenation therapies. In this episode of the AWS Health Innovation Podcast, Sanjit Misra from AWS hosts an in-depth conversation with Daniel Ives, the CEO and Founder of Shift Bioscience. Daniel's team has made significant breakthroughs in developing cell rejuvenation therapies using advanced cell simulation models and aging biomarkers to tackle the underlying driver of many age-related diseases.

1. How did Daniel Ives' research journey lead to the founding of Shift Bioscience?
• Daniel's path from studying mitochondrial mutations to founding Shift Bioscience illustrates a fascinating evolution in aging research. This transition underscores the potential for AI-driven approaches to revolutionize our understanding of cellular aging and rejuvenation.
2. What innovative approach does Shift Bioscience use to accelerate aging research?
• Shift Bioscience employs groundbreaking cell simulations that compress centuries of experiments into mere years. This approach enables rapid discovery of safe rejuvenation pathways, potentially fast-tracking the development of anti-aging therapies.
3. How does Shift Bioscience position itself in the field of longevity research?
• Operating at the cutting edge of longevity research, Shift Bioscience focuses on fundamental aging processes. Their work challenges conventional approaches, pushing the boundaries of what's possible in cellular rejuvenation and age-related disease prevention.
4. What is the significance of Shift Bioscience's single cell aging clock?
• The single cell aging clock represents a significant advancement in aging research. This machine learning-powered tool enables precise prediction of epigenetic age from single cell data, dramatically accelerating the pace of experimentation and discovery.
5. How does Shift Bioscience address the risks associated with cell rejuvenation?
• Shift Bioscience has discovered novel methods to rejuvenate cells without dangerous side effects. Their approach, including a single gene intervention, avoids the pluripotency risks associated with traditional Yamanaka factors, potentially offering safer anti-aging therapies.
6. How does cloud computing contribute to Shift Bioscience's research capabilities?
• By leveraging cloud computing, Shift Bioscience has revolutionized the speed and scale of aging experiments. Their ability to run hundreds of thousands of simulations in days demonstrates the power of combining biotechnology with advanced computing resources.

To learn more about Shift Bioscience and their groundbreaking work in cell rejuvenation, visit their website at https://www.shiftbioscience.com/.

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

Unlock the secrets of your metabolism with a single breath. On this episode of the AWS Health Innovation Podcast, Mike Tarselli, Specialist Leader for HCLS Data & AI, explores the cutting-edge world of breath-based health tech with Daniel Tal Mor, Founder & CEO of Lumen. Discover how this innovative device is transforming the way we approach metabolic health, offering real-time insights through a simple smartphone app.

1. How does Lumen's device measure metabolism?
• Lumen's innovative technology measures metabolism through a single breath, providing real-time data on whether the body is burning fat or carbs. This approach democratizes metabolic health monitoring, offering an accessible alternative to expensive hospital equipment.
2. What inspired the creation of Lumen?
• Lumen was born from the combined expertise of twin PhDs, Michal and Merav, who specialized in cardiac arrhythmia. Their backgrounds in nutrition and endurance athletics, coupled with frustration over limited nutrition study data, led to the development of this revolutionary metabolic measurement tool.
3. How does the Lumen device analyze breath?
• The device analyzes CO2, humidity, temperature, and airflow in exhaled breath to determine metabolic state. This sophisticated technology translates complex physiological processes into actionable insights for users seeking to optimize their health.
4. How does Lumen leverage data for personalized health recommendations?
• With over 66 million metabolic measurements from 300,000+ customers, Lumen offers highly personalized health recommendations. The platform's ability to provide tailored interventions based on vast datasets sets a new standard in digital health coaching.
5. What role does cloud technology play in Lumen's functionality?
• Lumen's cloud-based processing enables continuous algorithm improvement and personalization without hardware changes. This approach allows the platform to adapt to various user needs, from weight loss to athletic performance optimization.
6. How does AI contribute to Lumen's health insights?
• Lumen's AI analyzes diverse data points to provide context-appropriate health recommendations. The company's collaboration with AWS facilitates large-scale data storage and processing, driving continuous improvements in metabolic science.
7. What research partnerships is Lumen involved in?
• Lumen is partnering with universities and hospitals to advance metabolic health research. The company's unique at-home device enables novel studies, potentially reshaping our understanding of metabolism in various populations and conditions.
8. What does Lumen envision for the future of personalized metabolic health?
• Lumen anticipates a growing focus on metabolic health, partly due to weight loss medication side effects. The company's ability to detect menstrual cycle phases and menopause onset through metabolic measurements showcases the potential for highly personalized health insights.

To learn more about Lumen and their innovative metabolic health technology, visit https://www.lumen.me/. Use coupon code AWS for a special discount on a Lumen device.

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

The aging population is creating unprecedented challenges in senior care. In this episode of the AWS Health Innovation Podcast, Guy Spigelman, EMEA lead for Healthcare and Life Sciences Startups at AWS, speaks with Nevo Elmalem, Co-Founder & CTO of Sensi.ai. Sensi is on a mission to unleash growth, productivity, and purpose for home care agencies, empowering every senior to safely age in place through care intelligence.

Sensi.AI's sophisticated audio AI platform transforms home care by predicting and detecting care events while maintaining privacy. It equips agencies with essential insights into senior health, enabling timely interventions and tailored care plans. This reduces hospitalizations, enhances caregiver-client relationships, and prolongs service durations, allowing seniors to stay at home longer.

1. How did personal experiences shape the founding of Sensi.ai?
• Nevo Elmalem's journey to founding Sensi.ai was inspired by two powerful personal experiences. These stories highlighted the critical need for holistic assessment and safety in care environments, driving the innovation behind Sensi.ai's technology.
2. How does Sensi.ai's technology enable aging in place?
• Sensi.ai's audio-based monitoring system allows seniors to remain safely in their homes. Sensi's AI technology is trusted by home care agencies across the nation for its ability to identify over 100 critical insights, including early indicators of respiratory infections, UTIs, care resistance, cognitive shifts, and emergencies like falls. Our customers share how Sensi is preserving independence and quality of life for the older adults while also saving lives by enabling timely intervention. .
3. What gives Sensi.ai a competitive edge in the eldercare market?
• Sensi's AI, powered by the home care industry’s largest proprietary dataset with over 1,000 years of audio data, offers unmatched precision, privacy, and comprehensiveness. Unlike traditional senior care technologies that rely on user input, Sensi operates continuously, requiring no action from seniors—an approach especially vital for emergencies and dementia care. By shifting from reactive to proactive care, Sensi enables agencies to craft personalized care plans and provide seamless support, even in caregivers' absence. This ensures consistent, tailored care for seniors while enhancing communication with families, caregivers, and healthcare providers for a holistic care experience.
4. How did Sensi.ai approach startup challenges and funding?
• Nevo details Sensi.ai's lean approach to product development and funding. Their strategy of demonstrating traction before seeking VC investment proved successful, resulting in over $53 million raised to support their growth and innovation.
5. Can you share examples of AI's impact on eldercare through Sensi.ai?
• Sensi benefits seniors, families, and care teams alike. It acts as a safety net by detecting medication errors, falls, cognitive decline, and predicting infections like UTIs or respiratory issues reducing hospitalizations. Additionally, it provides insights into caregiver-client dynamics for optimal match increasing caregiver retention. As a care copilot, Sensi supports home care agencies in delivering better care and driving growth.
6. What technologies power Sensi.ai's eldercare solution?
• Sensi.ai leverages AWS services and combines hardware, IoT, and AI technologies. This innovative tech stack addresses the growing demand for effective, scalable eldercare solutions, positioning Sensi.ai at the forefront of the eldercare revolution.

To learn more about Sensi.ai and their innovative approach to eldercare, visit their website at https://sensi.ai/.

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

Transforming real-world medical data into actionable evidence in minutes, not years - this is the revolutionary approach of Atropos Health. On today's episode of the AWS Health Innovation Podcast, host Sanjit Misra has a fascinating conversation with Dr. Brigham Hyde, CEO and Co-Founder of Atropos Health. from technology developed and tested at Stanford, Atropos Health is reshaping the landscape of evidence-based medicine, providing on-demand evidence from real-world data to close critical gaps in healthcare and life sciences. Let's dive into how Atropos Health is elevating clinical outcomes, accelerating research, and driving operational efficiency.

1. How did Atropos Health evolve from an academic project to an industry disruptor?
• Atropos Health's journey exemplifies the power of translating research into real-world impact. The company's mission to accelerate evidence generation aligns well with the growing demand for data-driven healthcare decision-making, showcasing how academic innovations can transform into practical solutions for the healthcare industry.
2. What critical healthcare challenge does Atropos address?
• Atropos tackles the significant gap in high-quality evidence for many medical decisions. By rapidly generating real-world evidence, they aim to improve patient outcomes across diverse populations, including traditionally underrepresented groups, thus addressing a crucial need in healthcare decision-making.
3. How does GENEVA OS™(Generative Evidence Acceleration Operating System) revolutionize healthcare research?
• Atropos Health’s GENEVA OS a critical infrastructure layer for the healthcare ecosystem that can rapidly, accurately, and transparently convert healthcare data into personalized evidence' streamlines complex data analysis and makes it accessible to non-technical users. This innovation significantly reduces the time and resources needed for healthcare research, potentially accelerating medical advancements and democratizing access to data-driven insights.
4. What role does AI play in Atropos Heath's clinical insights generation?
• Chat RWD™, Atropos Healths' AI co-pilot, transforms clinical questions into real-world evidence studies in seconds. This technology has the potential to revolutionize point-of-care decision-making, enabling physicians to access personalized, evidence-based insights instantly, thereby enhancing the quality and efficiency of patient care.
5. Can you provide examples of Atropos Health's real-world impact on patient care?
• Atropos Health's technology has demonstrated tangible benefits in clinical settings, from avoiding unnecessary tests to resolving treatment debates and improving shared decisionmaking. These case studies highlight the potential for data-driven approaches to improve healthcare efficiency and patient outcomes, showcasing the practical applications of their innovative platform.
6. How does Atropos Health plan to expand its impact on global healthcare?
• I nternational expansion plans include addressing the need for diverse, representative medical evidence. By enabling global access to real-world data insights, they aim to reduce healthcare disparities and improve treatment efficacy worldwide, potentially transforming healthcare decision-making on a global scale.

To learn more about how Atropos Health is revolutionizing healthcare decision-making with real-world data, visit their website at https://www.atroposhealth.com.

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

In this episode of the AWS Health Innovation Podcast, Yin He, Principal Business Development for Healthcare & Life Sciences Startups at AWS, explores the future of scientific research with Bogdan Knezevic, Co-Founder & CEO of Kaleidoscope Bio. Discover how their innovative software platform is transforming R&D by making it more collaborative, reproducible, and scalable across the life sciences industry.

1. How is Kaleidoscope Bio revolutionizing R&D in the biotech and pharma industries?
• Kaleidoscope's platform streamlines R&D processes by integrating data from various sources, enhancing collaboration, and improving decision-making. This approach accelerates therapeutic development and helps companies reach clinical trials more efficiently.
2. What role does data play in driving decisions in life sciences research?
• The Kaleidoscope platform aggregates critical information, allowing stakeholders to visualize and analyze data effectively. This empowers R&D leaders to make informed decisions, potentially reducing unnecessary costs and accelerating time-to-market for life-saving therapies.
3. How does Kaleidoscope Bio cater to the diverse needs of different labs?
• Kaleidoscope offers customized product versions to accommodate varying technological infrastructures in life science companies. Their flexible approach ensures that both cutting-edge labs and those using basic tools can benefit from streamlined data management and improved collaboration.
4. What design principles guide Kaleidoscope's platform development?
• Kaleidoscope prioritizes user-friendly interfaces to simplify complex workflows for scientists. Features like smart field mapping and one-click data highlighting demonstrate the platform's commitment to enhancing productivity in research environments.
5. How does Kaleidoscope's platform help measure R&D efficiency and impact?
• The platform provides tools for assessing research productivity and identifying bottlenecks in the drug development process. This transparency enables both individual scientists and leadership to evaluate performance and optimize resource allocation.
6. What inspired the creation of Kaleidoscope Bio?
• Bogdan Knezevic's background in genomics and biotech startups inspired Kaleidoscope's mission. The company's focus on solving fundamental R&D challenges reflects a deep understanding of the industry's needs and the potential for significant time and cost savings in scientific research.

To learn more about Kaleidoscope Bio and their innovative R&D platform, visit kaleidoscope.bio.

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

Suffering from chronic musculoskeletal pain? Sword Health is revolutionizing access to quality care with their cutting-edge digital therapy platform. Join Sanjit Misra, Senior Technical Product Manager at AWS, as he interviews Vijay Yanamadala, Chief Medical Officer at Sword Health, to explore how AI and virtual physical therapy are transforming the treatment landscape.

1. How is Sword Health overcoming barriers to accessing quality care?

• Sword Health provides tablets and mobile hotspots to ensure equitable access for all patients, regardless of location or socioeconomic status. Their platform democratizes care by reaching underserved communities and healthcare deserts.

2. How does Sword Health leverage AI to enhance physical therapy?

• Computer vision AI meticulously tracks patient movements during exercises, sending detailed data to physical therapists for personalized feedback and progression. This technology maximizes therapist bandwidth while ensuring optimal care.
• Sword Health's "Predict" AI model identifies patients at risk for unnecessary surgeries, leading to a 60% reduction in surgeries for those using their platform. This approach prioritizes conservative, evidence-based treatment.

3. How does Sword Health personalize the patient experience?

• Patients undergo comprehensive onboarding, including questionnaires and video calls with physical therapists to discuss goals and limitations. This personalized approach ensures tailored exercise programs from the outset.
• The AI assistant "Phoenix" guides patients through exercises with real-time feedback, gamification, and progress tracking, boosting engagement and adherence. Patients average 33 sessions compared to 4 for traditional in-person PT.

4. How does Sword Health measure and optimize patient outcomes?

• Sword Health measures patient-reported outcomes aligned with individualized goals, allowing real-time adjustments to ensure sustainable improvements in pain, disability, and work productivity.

Learn more about Sword Health's innovative digital therapy platform here.

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

Rune Labs is pioneering the use of real-world data to revolutionize therapy development for neurodegenerative diseases like Parkinson's. In this episode, Mike Tarselli, Specialist Leader - HCLS Data & AI at AWS, talks to Brian Pepin, CEO of Rune Labs, about the company's innovative approach to digital biomarkers and how they're working to make a difference in the lives of patients.

1. What is Rune Labs' approach to decoding neurodegenerative diseases?
   • Rune Labs uses real-world data to accelerate therapeutic development for neurodegenerative diseases like Parkinson's, providing access to engaged clinicians, patients, and longitudinal datasets. As precision medicine gains traction, companies like Rune Labs are well-positioned to drive innovation in this space.
2. How are digital biomarkers revolutionizing disease tracking?
   • Rune Labs aims to quantify subjective clinical assessments using standardized sensing and data formats, offering a more objective, repeatable, and scalable way to track disease progression and medication effects compared to traditional rating scales. This approach holds promise for neurology, which lacks quantitative biomarkers.
3. What is StrivePD, and how does it reimagine dopamine management?
   • StrivePD, Rune Labs' flagship product, is a dopamine care management system that automatically detects and classifies Parkinson's symptoms using the Apple Watch, providing insights to patients and clinicians for better disease management. This innovative solution reduces cognitive burden and improves access to care.
4. How is Rune Labs empowering precision clinical trials?
   • By leveraging data and their network, Rune Labs aims to shift the economics of phase 3 clinical trials, enabling more precise measurements and identifying better responders for promising Parkinson's drugs. Their approach could make economically viable trials for disease-modifying therapies a reality.
5. How is Rune Labs harnessing AI for personalized care?
   • Rune Labs utilizes machine learning on dense time series data and large language models to identify patterns predictive of medication responses, progression events, and risk factors, enabling contextualized feedback and virtual patient coaching. This multimodal approach exemplifies the potential of AI in healthcare.
6. What advice does Brian Pepin, Rune Labs' CEO, have for founders?
   • Brian Pepin advises founders to clearly identify and focus on one major risk at a time (scientific, clinical, or business model) and ensure early team and investors are committed to the long-term vision in healthcare, which often spans 10+ years.

To learn more about Rune Labs and their innovative approach to neurodegenerative diseases, visit their website or learn more about their Parkinson’s patient app, StrivePD, by visiting www.strivepd.com.

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

Anterior is on a mission to relieve doctors and nurses of administrative burden, starting with transforming the prior authorization process. In this episode of the AWS Health Innovation Podcast, Abdel Mahmoud, MD, CEO and Co-Founder of Anterior, shares how the company's generative AI technology is changing the game for healthcare professionals.

1. What inspired Abdel Mahmoud's vision for Anterior?
   • Abdel shares his journey from immigrant roots to medical school, where he realized technology's potential to improve healthcare upstream. He recounts experiences at Facebook, UCL, and Google before co-founding Anterior to reduce healthcare's $1 trillion administrative burden.
2. How does Anterior bridge the gap between healthcare and tech?
   • While healthcare faces resource constraints, clinicians show empathy despite challenges; tech startups prioritize rapid iteration. Anterior aligns provider and payer incentives through AI-powered clinical decisioning tools, contrasting the two worlds.
3. How does Anterior leverage large language models?
   • Anterior ingests unstructured clinical data, using large language models to understand medical jargon, surface insights, and increase clinician productivity reviewing cases like prior authorizations. Rigorous evaluation pipelines ensure model accuracy.
4. What has Anterior learned about designing for seamless user experiences?
   • A key learning has been the importance of streamlined user experiences, enabling clinicians to quickly validate AI recommendations with minimal effort, even on mobile devices.
5. What was Anterior's fundraising journey, and what advice does Abdel offer founders?
   • The path involved an accelerator, seed round from Sequoia, then Series A from NEA to scale. Advice includes joining accelerators, demonstrating traction, articulating an ambitious vision, and prioritizing strategic thinking as CEO.

To learn more about Anterior's mission to reduce the administrative burden in healthcare, visit their website.

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

On today's episode we learn all about the immune system with Adam Laing, Co-founder & Chief Scientific Officer of IMU Biosciences, as he joins Alex Merwin, Head of Growth for Healthcare & Life Science Startups at AWS, on the AWS Health Innovation Podcast. IMU Biosciences is transforming our understanding of the immune system by leveraging AI-powered immune profiling to create unprecedented insights into health and disease, to advance precision medicine through collaborations with leading pharma, research organizations, and academic institutions.

1. How is IMU Biosciences unlocking immune insights?

• IMU Biosciences' pioneering technology measures 80 million data points across 2,000 immune cell subsets, from a small blood sample, providing unprecedented resolution into an individual's immune profile. This enables precision medicine approaches across disease areas like cancer, autoimmunity, and cell therapy.

2. What is the potential of predictive immune profiling?

• By deeply characterizing immune systems, IMU aims to predict disease progression and treatment responses. Their machine learning analytics identify immune signatures that can stratify patients based on how effectively they will respond to therapies.

3. How does IMU Biosciences foster a collaborative culture?

• With a team spanning immunology, data science, engineering, and operations, IMU fosters a collaborative culture focused on solving complex problems. Their network and reputation helped secure early industry partnerships.

4. What is IMU Biosciences' vision for scaling precision immunology?

• After demonstrating their technology's potential during COVID-19 research, IMU raised a Series A to commercialize and build a predictive immune data platform. Their long-term vision is enabling preventative screening for disease risk.

5. How does IMU Biosciences leverage advances in flow cytometry?

• IMU leverages advances in flow cytometry instrumentation, labeling 75 markers to phenotype cells at unprecedented resolution. Robust processes ensure scalability by accounting for technical variability across samples.

Learn more about IMU Biosciences here to explore their pioneering work in unlocking the complexity of the immune system and advancing precision medicine.

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

In this episode of the AWS Health Innovation Podcast, host Eric Zimmerman, Principal Healthcare & Life Sciences BD at AWS, sits down with Gabriel Jones, CEO of Proprio, a company revolutionizing surgery through AI, computer vision, and augmented reality. Proprio's mission is to enhance surgical precision and decision-making with real-time, interactive 3D visualization and simulations.

1. How is Proprio transforming the surgical landscape with AI?

• Gabriel Jones shares insights on how AI and advanced imaging will revolutionize surgery, enabling real-time data visualization and predictive analytics. This aligns with Proprio's mission to enhance surgical precision through intelligent technology.

2. What was the key to Proprio's innovative approach?

• The founding team's diverse expertise in neurosurgery, computer vision, and sensor systems allowed Proprio to converge disparate data sources into a novel imaging modality. This interdisciplinary approach drives innovation in surgical visualization.

3. How did Proprio navigate the product development process?

• While Proprio's core thesis endures, the company embraced an iterative product development cycle, learning that initial concepts require refinement through user feedback and prototyping. Constant adaptation is key in deep tech.

4. What factors have enabled Proprio's "physical AI" approach?

• Recent breakthroughs in AI, sensors, and data integration have created an opportune environment for Proprio's "physical AI" approach of bridging the physical and digital realms in healthcare. Timing is crucial for deep tech success.

5. How does Proprio envision democratizing healthcare innovation?

• Proprio envisions enabling clinicians to invent novel products and services powered by its data platform, while pressuring incumbents to accelerate innovation. This could democratize healthcare solutions development.

6. What is Proprio's focus for talent acquisition?

• As an AI company focused on computer vision, robotics and engineering, Proprio is actively hiring top talent to drive partnerships and growth in its transformative vision for surgery and healthcare.

Learn more about Proprio and their innovative surgical technology on their website.

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.